- April 25 - 27, 2022
- - ET
- - ET
- - ET
Event LocationBethesda North Marriott
Hotel & Conference Center
5701 Marinelli Road
Rockville, MD 20852
Goals and Objectives:
- Provide a forum for open discussion between industry, academic, and government scientists regarding challenges and experiences encountered in oligonucleotide drug development.
- Seek feedback from industry, academia, and other stakeholders on the current progress and challenges in oligonucleotide research and drug development.
- Assess the impact of regulations and guidance on oligonucleotide drug development and discuss possible avenues for changes and improvements.
- Facilitate open discussions among all industry researchers and regulatory agencies regarding oligonucleotide drug development.
Who Should Attend:
The 2022 DIA/FDA Oligonucleotide-based Therapeutics Conference is intended for a diverse group of scientists responsible for the evaluation of safety and efficacy of oligonucleotide products including interested industry, academic and government parties involved in ongoing efforts in the research and development of oligonucleotides.
The primary audience includes leading academic experts, interested pharmaceutical companies, regulatory agencies, patient advocacy groups, non-profit organizations, scientists, clinicians from regulatory, academic, industrial and other healthcare sectors, scientists involved in drug development in those same industries, regulatory scientists, experts and leaders from industry, academia, regulatory government agencies in the US and abroad, patient representatives, healthcare providers, and pharmacokineticists (clinical, preclinical, and toxicokinetics) who are involved in oligonucleotide drug development or supporting research.
If to DIA:
Robin M. Weinick, Senior Vice President and Managing Director, Americas
Global Program Officer
Drug Information Association (DIA)
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595
If to FDA:
Ronald Wange, Ph.D.
Associate Director for Pharmacology and Toxicology
Bldg 22, Room 3342
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993